The use of cyclosporine in dermatology: Part IIRYAN, Caitriona; AMOR, Karrie T; MENTER, Alan et al.Journal of the American Academy of Dermatology. 2010, Vol 63, Num 6, pp 949-972, issn 0190-9622, 24 p.Article

Cyclosporin A inhibits the replication of diverse coronavirusesDE WILDE, Adriaan H; ZEVENHOVEN-DOBBE, Jessika C; VAN DER MEER, Yvonne et al.Journal of general virology. 2011, Vol 92, pp 2542-2548, issn 0022-1317, 7 p., 11Article

The use of cyclosporine in dermatology: Part IAMOR, Karrie T; RYAN, Caitriona; MENTER, Alan et al.Journal of the American Academy of Dermatology. 2010, Vol 63, Num 6, pp 925-946, issn 0190-9622, 22 p.Article

Cross-reactivities of cyclosporin G (NVa²-cyclosporin) and metabolites in cyclosporin A immunoassaysYATSCOFF, R. W; LANGMAN, L. J; LEGATT, D. F et al.Clinical chemistry (Baltimore, Md.). 1993, Vol 39, Num 6, pp 1089-1092, issn 0009-9147Conference Paper

Neuromyopathie toxique induite par la ciclosporine = Cyclosporin-induced toxic neuromyopathyGUENNOC, A.-M; CORCIA, P; AI-NAJJAR, A et al.Revue neurologique (Paris). 2005, Vol 161, Num 2, pp 221-223, issn 0035-3787, 3 p.Article

CiclosporinePAUL, C; GARAT, H.Annales de dermatologie et de vénéréologie. 2011, Vol 138, Num 12, pp 836-838, issn 0151-9638, 3 p.Article

Elevating bioavailability of cyclosporine A via encapsulation in artificial oil bodies stabilized by caleosinCHEN, Miles C. M; WANG, Jui-Ling; TZEN, Jason T. C et al.Biotechnology progress. 2005, Vol 21, Num 4, pp 1297-1301, issn 8756-7938, 5 p.Article

La ciclosporine topique: Quand et comment l'utiliser ?MILAZZO, Solange; DRIMBEA, Andrei; JANY, Benjamin et al.Pratiques en ophtalmologie. 2014, Vol 8, Num 76, pp 166-169, issn 2106-9735, 4 p.Article

Cyclosporin A improves the selection of cells transfected with the puromycin acetyltransferase geneGUOPING ZHENG; LYONS, J. Guy.BioTechniques. 2002, Vol 33, Num 1, pp 32-36, issn 0736-6205, 3 p.Article

Cyclosporine for SJS/TEN: A Case Series and Review of the LiteratureREESE, Drew; HENNING, J. Scott; ROCKERS, Kyle et al.Cutis (New York, NY). 2011, Vol 87, Num 1, pp 24-29, issn 0011-4162, 6 p.Article

Modulation by cyclosporin-A of mononuclear cell distribution during experimental allergic encephalomyelitisRUMJANEK, V. M; SMITH, L. A; MORLEY, J et al.International journal of immunopharmacology. 1984, Vol 6, Num 2, pp 99-104, issn 0192-0561Article

Combination Strategy to Increase Cyclosporin A Productivity by Tolypocladium niveum Using Random Mutagenesis and Protoplast TransformationLEE, Mi-Jin; CAC THI PHUNG DUONG; HAN, Kyuboem et al.Journal of microbiology and biotechnology. 2009, Vol 19, Num 9, pp 869-872, issn 1017-7825, 4 p.Article

Sulphated polysaccharides : New insight in the prevention of cyclosporine a-induced glomerular injuryJOSEPHINE, Anthony; COOTHAN KANDASWAMY VEENA; AMUDHA, Ganapathy et al.Basic & clinical pharmacology & toxicology (Print). 2007, Vol 101, Num 1, pp 9-15, issn 1742-7835, 7 p.Article

Experience with cyclosporineLANGONE, A. J; HELDERMAN, J. H.Transplantation proceedings. 2004, Vol 36, Num 2S, pp 59-63, issn 0041-1345, 5 p., SUPArticle

Experience with cyclosporineBILLING-GRIMA, M; WOLF, P.Transplantation proceedings. 2004, Vol 36, Num 2S, pp 285-290, issn 0041-1345, 6 p., SUPArticle

Comment un dermatologue libéral peut surveiller un traitement court du psoriasis par la ciclosporine = How will a private practice dermatologist supervise short treatment with cyclosporineSTEINER, H. G.Les Nouvelles dermatologiques. 2000, Vol 19, Num 3, pp 205-206, issn 0752-5370Conference Paper

Cyclosporine A-induced changes to erythrocyte redox balance is time course-dependentLEXIS, Louise A; RICHARDS, Ross S; FASSETT, Robert G et al.Basic & clinical pharmacology & toxicology (Print). 2005, Vol 97, Num 3, pp 135-140, issn 1742-7835, 6 p.Article

Cyclosporin nanoparticulate lipospheres for oral administrationBEKERMAN, Tania; GOLENSER, Jacob; DOMB, Abraham et al.Journal of pharmaceutical sciences. 2004, Vol 93, Num 5, pp 1264-1270, issn 0022-3549, 7 p.Article

Experience with cyclosporineSANDRINI, S; SETTI, G; TARDANICO, R et al.Transplantation proceedings. 2004, Vol 36, Num 2S, pp 152-157, issn 0041-1345, 6 p., SUPArticle

Derivatives of cyclosporin compatible with antibody-based assays. I: The generation of [¹²⁵I]-labeled cyclosporinMAHONEY, W. C; ORF, J. W.Clinical chemistry (Baltimore, Md.). 1985, Vol 31, Num 3, pp 459-462, issn 0009-9147Article

Cyclosporine monitoringBURCKART, Gilbert J; CANAFAX, Daniel M; YEE, Gary C et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 7-8, pp 1277-1280, issn 1060-0280, 4 p.Article

From cyclosporine to the futurePONTICELLI, C; TARANTINO, A; CAMPISE, M et al.Transplantation proceedings. 2004, Vol 36, Num 2S, pp 557S-560S, issn 0041-1345, SUPArticle

The use of ciclosporin in psoriasisBERTH-JONES, John.Journal of dermatological treatment. 2005, Vol 16, Num 5-6, pp 258-277, issn 0954-6634, 20 p.Article

Préparation d'un collyre de ciclosporine à 2 % = Cyclosporine 2% eye drops preparationCHAST, F; LEMARE, F; LEGEAIS, J.-M et al.Journal français d'ophtalmologie. 2004, Vol 27, Num 6, pp 567-576, issn 0181-5512, 10 p., CAH1Article

Cyclosporine abrogation of second-set rejection: dependence upon major histocompatibility complex disparitySCHULAK, J. A; ENGELSTAD, K.The Journal of surgical research. 1985, Vol 38, Num 4, pp 400-406, issn 0022-4804Article